Lunar warns of lower revenues
Bone densitometry vendor Lunar last month announced that its third-quarter revenues would likely decline compared with the same quarter last year. Lunar of Madison, WI, pointed to below-average sales of densitometers in the U.S. and Asia as a reason for
Bone densitometry vendor Lunar last month announced that its third-quarter revenues would likely decline compared with the same quarter last year. Lunar of Madison, WI, pointed to below-average sales of densitometers in the U.S. and Asia as a reason for the anticipated down quarter (end-March 31).
While the company attributed the dip in Asian sales to the region's recent currency difficulties, U.S. demand has been shifting away from traditional hospital markets toward lower priced systems for physician offices. In an effort to improve access to these emerging markets, Lunar is implementing new distribution channels. The company expects to soon announce new national distributor relationships for its existing physician-office products, as well as its Achilles ultrasound densitometer, which is pending Food and Drug Administration premarket approval.
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Key MRI Findings Predictive of Treatment Response for Unresectable Hepatocellular Carcinoma
July 14th 2025For patients with unresectable hepatocellular carcinoma, a pre-treatment MRI finding of LI-RADS tumor in vein was associated with over an 86 percent lower likelihood of responding to transcatheter arterial chemoembolization (TACE) and targeted immunotherapy.
